Zurcher Kantonalbank Zurich Cantonalbank Has $5.83 Million Stock Holdings in Qiagen N.V. (NYSE:QGEN)

Key Points

• Zurcher Kantonalbank Zurich Cantonalbank reduced its holdings in Qiagen N.V. by 13.9%, after selling 23,826 shares in the first quarter, leaving them with 147,826 shares valued at approximately $5.8 million.
• Several institutional investors, including Brown Brothers Harriman and Tower Research Capital, increased or initiated positions in Qiagen, indicating robust interest in the stock.
• Qiagen's share price received upgraded targets from analysts, with Bank of America projecting a price increase from $50 to $53, while the stock currently has an average rating of "Hold" and a target price of $49.40.

Zurcher Kantonalbank Zurich Cantonalbank lowered its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 13.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,826 shares of the company's stock after selling 23,826 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.07% of Qiagen worth $5,826,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in QGEN. LPL Financial LLC boosted its stake in Qiagen by 2.6% in the fourth quarter. LPL Financial LLC now owns 17,240 shares of the company's stock worth $768,000 after purchasing an additional 432 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Qiagen by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock valued at $397,937,000 after buying an additional 77,119 shares during the last quarter. Orion Portfolio Solutions LLC lifted its position in Qiagen by 49.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 17,391 shares of the company's stock worth $774,000 after buying an additional 5,770 shares in the last quarter. Brown Brothers Harriman & Co. bought a new stake in Qiagen during the 4th quarter worth about $37,000. Finally, Franklin Resources Inc. grew its holdings in Qiagen by 63.5% during the 4th quarter. Franklin Resources Inc. now owns 143,047 shares of the company's stock worth $6,370,000 after acquiring an additional 55,577 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Trading Up 1.1%

QGEN stock traded up $0.56 during midday trading on Friday, reaching $49.90. The company's stock had a trading volume of 1,431,518 shares, compared to its average volume of 1,479,522. The business's 50-day simple moving average is $47.54 and its 200-day simple moving average is $43.43. The company has a quick ratio of 2.83, a current ratio of 3.37 and a debt-to-equity ratio of 0.40. Qiagen N.V. has a 52 week low of $37.63 and a 52 week high of $51.88. The stock has a market cap of $11.09 billion, a PE ratio of 125.11, a price-to-earnings-growth ratio of 2.51 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The company had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same quarter in the prior year, the business posted $0.44 EPS. The firm's quarterly revenue was up 5.2% on a year-over-year basis. As a group, sell-side analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Dividend Announcement

The business also recently announced a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were given a dividend of $0.25 per share. This represents a dividend yield of 52.0%. The ex-dividend date was Wednesday, July 2nd. Qiagen's payout ratio is presently 62.50%.

Wall Street Analyst Weigh In

QGEN has been the subject of a number of research analyst reports. Barclays started coverage on shares of Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price for the company. Bank of America boosted their price objective on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Redburn Atlantic downgraded Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Wall Street Zen lowered Qiagen from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, Robert W. Baird boosted their target price on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $49.40.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.